Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Molecular Diagnostics Korea (MDxK) is a South Korean life-science tools and scientific solutions company focused on supplying instruments, consumables, and technical services for molecular research and diagnostics. The company serves research and laboratory customers across multiomics and molecular biology, biologics and cellular biology, structural biology, and biobanking/sample management. Rather than developing a therapeutic drug pipeline, MDxK operates as a commercial distributor and application-support organization for advanced research technologies from global partners. Founded in 2007, the company built a position in the Korean life-science market and in March 2025 DKSH announced an agreement to acquire it to strengthen DKSH Technology’s scientific solutions business in South Korea. MDxK appears to continue operating as an active business following the announced acquisition.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Molecular Diagnostics Korea.